Angiotensin II Type 1 receptor antagonists in chronic heart failure

Bibliography

• REMME WJ, SWEDBERG K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur: Heart J. (2001) 22:1529–1560.
   Web of Science ®Google Scholar
• ••Most recent treatment guidelines for heart failure patients edited by the European Heart Association.
   Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• McMURRAY JJV: Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart (2001) 86:97–103.
   PubMed Web of Science ®Google Scholar
• PACKER M: Pathophysiology of heart failure. Lancet (1992) 340:88–95.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• WEBER KT: Cardioreparation in hypertensive heart disease. Hypertension (2001) 38:588–591.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the mechanism of development of hypertensive heart disease.
   Google Scholar
• SWEDBERG K, ENEROTH P, KJEKSHUS J, SNAPPIN S: Effects of enalapril and neuroendocrine activation on prognosis in severe heart failure (follow-up of the CONSENSUS trial). Am.j Cardiol. (1990) 66:40D–44D.
   Google Scholar
• ACE INHIBITOR MYOCARDIAL INFARCTION COLLABORATIVE GROUP: Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100 000 patients in randomized trials. Circulation (1998) 97:2202–2212.
   Google Scholar
• ••Review with guideline character for the use of ACEIs post myocardial infarction.
   Google Scholar
• BLOOD PRESSURE LOWERING TREATMENT TRIALISTS' COLLABORATION: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet (2000) 356:1955–1964.
   PubMed Web of Science ®Google Scholar
• ••Overview on randomised clinical trials inhypertension in comparison to conventional treatment with n-blockers and calcium antagonists.
   Google Scholar
• GOODFRIEND TL, ELLIOTT ME, CATT KJ: Angiotensin receptors and their antagonists. N Engl. Med. (1996) 334:1649–1654.
   PubMed Web of Science ®Google Scholar
• OVERLACK A: ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms, and management. Drug Sal: (1996) 15:72–78.
   PubMed Web of Science ®Google Scholar
• URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. (1990) 265:2348–2357.
   Web of Science ®Google Scholar
• JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• CICOIRA M, ZANOLLA L, ROSSI A et al.:Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE/DD genotype. Am. Coll. Cardiol. (2001) 37:1808–1812.
   PubMed Web of Science ®Google Scholar
• CICOIRA M, ZANOLLA L, FRANCESCHINI L et al.: Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. .1 Cardiol. (2002) 89:403–407.
   Google Scholar
• BRINK M, DE GASPARO M, ROGG H, SCHMID A, STULZ P, BULLOCK G: Localization of the angiotensin II receptor subtypes in the human atrium. j MM. Cell. Cardiol. (1996) 28:1789–1799.
   PubMed Web of Science ®Google Scholar
• YAMADA T, HORIUCHI M, DZAU VJ: Angiotensin II Type 2 receptor mediates programmed cell death. Proc. Nati Acad. Si". (1996) 93:156–160.
   PubMed Web of Science ®Google Scholar
• SMITH RD, CHIU AT, WONG PC, HERBLIN WF, TIMMERMANS PBMWM: Pharmacology of nonpeptide angiotensin II receptor antagonists. Ann. Rev Pharmacol. Toxicol. (1992) 32:135–165.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the pharmacology of ATI antagonists.
   Google Scholar
• BURNIER M, MAILARD M: The comparative pharmacology of angiotensin II receptor antagonists. Blood Press. (2001) 10\(Suppl. 1):6–11.
   Google Scholar
• •Comparative review on pharmacology and clinical pharmacology of ATi antagonists.
   Google Scholar
• THORIVIANN PA: Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opin. Pharmacother: (2000) 1:337–350.
   Google Scholar
• MAZZOLAI L, MAILLARD M, ROSSATJ,NUSSBERGERJ, BRUNNER HR, BURNIER M: Angiotensin II receptor blockade of three different ATi receptor antagonists. Hypertension (1999) 33:850–855.
   PubMed Web of Science ®Google Scholar
• ZIERHUT W, STUDER R, LAURENT D et al.: Left ventricular wall stress and sarcoplasmatic reticulum Ca2+-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and ATi-receptor blockade. Cardiovasc. Res. (1996) 31:758–768.
   PubMed Web of Science ®Google Scholar
• RUZICKA M, YUAN B, LEENEN FH: Effects of enalapril versus losartan on regression of volume overload induced cardiac hypertrophy in rats. Circulation (1994) 90:484–491.
   PubMed Web of Science ®Google Scholar
• CLAIR MJ, KROMBACH RS, COKER MLet al.: Angiotensin ATi receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition. Mol. Cell. Cardiol. (1998) 30:2355–2364.
   Google Scholar
• HAYASHI N, FUJIMURA Y, YAMAMOTO S, KOMETAMI M, NAKAO K: Pharmacological profile of valsartan, a non-peptide angiotensin II Type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan. Arzneim.-Forsch/Drug Res. (1997) 47:625–629.
   Google Scholar
• SMITS JF, VANKRIMPEN C, SCHOEMAKER RG, CLEUTJENS JP, DAEMEN MJ: Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. j Cardiovasc. Pharmacol (1992) 20:772–778.
   PubMed Web of Science ®Google Scholar
• LEVY D, GARRISON RJ, SAVAGE DD, KANNEL WB, CASTELLI WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl. j Med. (1990) 322:1561–1566.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB: left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. j Am. Coll. Cardiol (1989) 13:337–339.
   PubMed Web of Science ®Google Scholar
• CUOCOLO A, STORTO G, IZZO R et al: Effects of valsartan on left ventricular diastolic function in patients with mild to moderate essential hypertension: comparison with enalapril. Hypertens. (1999) 17:1759–1766.
   Web of Science ®Google Scholar
• CROZIER I, IKRAM H, AWAN N et al:Losartan in heart failure. Hemodynamic effects and tolerability. Circulation (1995) 91:691–697.
   PubMed Web of Science ®Google Scholar
• SWEET CS, RUCINSKA EJ: Losartan in heart failure: preclinical experiences and initial clinical outcomes. Ear: Heart j (1994) 15 (Suppl. D):139–144.
   Google Scholar
• DICKSTEIN K, CHANG P, WILLENHEIMER R et al.: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J. Am. Coll. Cardiol (1995) 26:438–445.
   PubMed Web of Science ®Google Scholar
• LANG RM, ELKAYAM U, YELLEN LG et al.: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. Am. Coll. Cardiol (1997) 30:983–991.
   PubMed Web of Science ®Google Scholar
• MAZAYEV W, FOMINA IG, KAZAKOV EN et al.: Valsartan in heart failure patients previously untreated with an ACEI. kit. j Cardiol (1998) 65:239–246.
   Web of Science ®Google Scholar
• GRANGER CB, ERTL G, KUCH J et al FOR THE STUDY OF PATIENTS INTOLERANT OF CONVERTING ENZYME INHIBITORS (SPICE) INVESTIGATORS: Randomized trial of candesartan cilexitil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart j (2000) 139:609–617.
   PubMed Web of Science ®Google Scholar
• RIEGGER GAJ, BOUZO H, PETR P et al.: Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224–2230.
   PubMed Web of Science ®Google Scholar
• HAVRANEK EP, THOMAS I, SMITH WB et al.: Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. j Am. Coll. Cardiol (1999) 33:1174–1181.
   PubMed Web of Science ®Google Scholar
• DUNSELMAN PHJM: Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int. j Cardiol (2001) 77:131–138.
   Google Scholar
• VASCOVO G, DALLA LIBERA L, SERAFINI F et al.: Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation (1998) 98:1742–1749.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• •The first clinical trial comparing ACEIs and ATI antagonists with respect to morbidity and mortality in heart failure patients.
   Google Scholar
• HOUGHTON AR, HARRISON M, COWLEY AJ: Haemodynamic, neurohumoral and exercise effects of losartan versus captopril in chronic heart failure: results of an ELITE trial substudy. Eur: Heart Fail. (1999) 1:385–393.
   PubMed Web of Science ®Google Scholar
• KONSTAM MA, PATTEN RD, THOMAS I et al.: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am. Heart j (2000) 139:1081–1087.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the losartan heart failure survival study ELITE II. Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• McKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation (1999) 100:1056–1064.
   PubMed Web of Science ®Google Scholar
• •Relevant clinical trial with candesartan in heart failure showing conflicting results.
   Google Scholar
• KIM S, YOSHIYAMA M, IZUMI Y et al:Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation (2001) 103:148–154.
   PubMed Web of Science ®Google Scholar
• AZIZI M, CHATELLIER G, THANH-TAM G, MURIETA-GEOFFROY D, MENARD J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation (1995) 92:825–834.
   PubMed Web of Science ®Google Scholar
• AZIZI M, LINHART A, ALEXANDER Jet al.: Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. Hypertens. (2000) 18:1139–1147.
   Google Scholar
• HOUGHTON AR, HARRISON M, COWLEY AJ, HAMPTON JR: Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial. Am. Heart.! (2000) 140:791–794.
   Google Scholar
• BARUCH L, ANAND I, COHEN IS et aL: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation (1999) 99:2658–2664.
   PubMed Web of Science ®Google Scholar
• GREMMLER B, KUNERT M, SCHLEITING H, ULBRICHT LJ: Improvement of cardiac output in patients with severe heart failure by use of ACEIs combined with the ATi-antagonist eprosartan. Eur: j Heart Fail (2000) 2:183–187.
   PubMed Web of Science ®Google Scholar
• MURDOCH DR, McDONAGH TA, FARMER R et al.: ADEPT: Addition of the ATi receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am. Heart.! (2001) 141:800–807.
   PubMed Web of Science ®Google Scholar
• TONKON M, AWAN N, NIAZP I et al.: Astudy of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int. j Clio. Pratt (2000) 54:11–18.
   PubMed Web of Science ®Google Scholar
• HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99:990–992.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl.' Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• •Clinical trial showing improvement of morbidity when combining ACE inhibition and high-dose ATI blockade.
   Google Scholar
• HEDNER T, OPARIL S, RASMUSSEN K et al.: A comparision of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am. Hypertens. (1999) 12:414–417.
   PubMed Web of Science ®Google Scholar
• PACKER M, POOLE-WILSON PA, ARMSTRONG PW et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 100:2312–2318.
   PubMed Web of Science ®Google Scholar
• PACKER M: Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.j Cardiac Fail. (2001) 7:176–182.
   PubMed Web of Science ®Google Scholar
• •Sophisticated discussion about surrogate markers and end points in heart failure.
   Google Scholar
• JONG P, DEMERS C, McKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials." Am. Coll Cardiol. (2002) 39: 463–470.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis of clinical trials with ATIantagonist in heart failure.
   Google Scholar
• SHARMA D, BUYSE M, PITT B, RUCINSKA EJ: Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Am.j Cardiol. (2000) 85:187–192.
   PubMed Web of Science ®Google Scholar
• HOWES LG, TRAN D: Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug. Sal (2002) 25:73–76.
   Google Scholar
• SWEDBERG K, PFEFFER M, GRANGER C et al.: Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Cardiac Fail. (1999) 5:276–282.
   PubMedGoogle Scholar
• DICKSTEIN K, KJEKSHUS J for the OPTIMAAL Trial Steering Committee and Investigators: Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). Am. Cardiol (2001) 87:766–771.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, McMURRAY J, LEIZOROVICZ A et al.: Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. (2000) 140:727–750.
   PubMed Web of Science ®Google Scholar
• KOSTIS JB, DAVIS BR, CUTLER J et al.:Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA (1997) 278:212–216.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SK et al. FOR THE LIFE STUDY GROUP: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• MANN JF, JULIUS S: The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. (1998) 7:176–183.
   PubMedGoogle Scholar
• TEERLINK JR, MASSIE B: The interaction of ACEIs and aspirin in heart failure: torn between two lovers. Am. Heart j (1999) 138:193–197.
   PubMed Web of Science ®Google Scholar
• HARJAI KJ, NUNEZ E, TURGUT T, NEWMAN J: Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. Am. Cardiol. (2001) 87:483–487.
   PubMed Web of Science ®Google Scholar
• •Interesting and clinically relevant observation on the potential harm of a frequently used combination.
   Google Scholar